Atlas Trials

Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

Clinical trial NCT03045393 · WITHDRAWN

Trial details

NCT number
NCT03045393
Sponsor
Duke University
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Breast Cancer Triple Negative
Start date
2017-04-17
Primary completion
2018-02-28
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.